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remains unclear. Second, the other endpoints of HBV DNA sup-
pression <1000 copies/ml and ALT normalization after 48 weeks
of PegIFN treatment was unsatisfactory. These results might be
worse after withdrawal of PegIFN therapy. Most of the patients
had to resume ETV treatment, which is terrible news for a doctor
to have to deliver to patients after a long course of PegIFN therapy.
Third, sustained and profound viral suppression is the main goal
of treatment. The ﬂuctuation of ALT and HBV DNA in the sequen-
tial therapymaymimic the phenomena of viral resistance to NA. It
has been reported that treatment related viral resistance blunts
histologic responses [2] and increases the rate of hepatocellular
carcinoma (HCC) even if rescue therapy is given [3]. Fourth, the
cost of treatment should also be considered. The per capita dispos-
able income is 18,311 RMB (2982 USD) in China 2013. The cost
of 48 weeks of PegIFN treatment is about 50,000 RMB
(8143 USD). Most of the treatment-naïve patients in China
may ﬁnd this treatment unaffordable. The cost of 48 weeks ETV
is only one ﬁfth of that. Fifth, the causative agent has not been
identiﬁed in this randomized controlled study. The treatment
arm underwent ETV withdrawal and PegIFN. Withdrawal of ADV
after 4–5 years of therapy has been shown to result in 39%
HBsAg loss in selected HBeAg negative patients [4]. To date, there
has never been a parallel study in HBeAg positive patients, and
there has never been a randomized control trial with PegIFN that
involves a control armwith NAwithdrawal only.We are anxiously
waiting for such a study, we can no longer make the assumption
that the treatment effect is entirely due to PegIFN. The correlation
between early ALT elevation after withdrawal of ETV with HBeAg
seroconversion and HBsAg loss supports this hypothesis. Finally,
the beneﬁt of HBeAg seroconversion should not be over
emphasized. HBeAg seroconversion has long been regarded as
an important treatment endpoint in hepatitis B therapy.
However, with the prevalence of pre-core or core mutation HBV
infection, HBeAg seroconversion is no longer an ideal endpoint.
Recently, Jessica Liu et al. demonstrated that HBV DNA seroclear-
ance, during the course of chronic hepatitis B, is the most signiﬁ-
cant factor in reducing risk for future HCC and HBeAg
seroclearance will not reduce future HCC further [5].
Combination endpoint with HBeAg seroconversion and HBV
DNA <1000 copies/ml may be more reasonable as the primary
endpoint. We do not know if the signiﬁcant difference between
the two cohorts was lost with this endpoint.
In summary, as clinicians, after weighing the pros and cons,
we do not think it is worthy of switching to PegIFN in patients
achieving virological suppression with ETV, except if the patient
refuse a long-term treatment.
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Letters to the EditorRepeated transarterial chemoembolization: An overﬁtting effort?
To the Editor:
We read with great interest the article by Adhoute et al. pub-
lished in Journal of Hepatology [1]. The authors developed a point
score system, the ABCR [standing for Alpha-fetoprotein (AFP),
Barcelona Clinic Liver Cancer (BCLC), Child-Pugh and Response],
to assist in the decision making on whether to retreat hep-
atocellular carcinoma (HCC) patients with multiple transarterial
chemoembolization (TACE) sessions. The study population con-
sisted of HCC patients treated with repeated consecutive TACE
sessions and the resulting signiﬁcant parameters from regression
analysis were used to build the score. In this way, the authors
differentiated three groups with different survival. The score
was consistently validated in training and conﬁrmatory cohorts
and a higher ABCR score after the ﬁrst TACE course was found
to be associated with patients at poorer prognosis who may not
beneﬁt from further TACE sessions.
Current guidelines do not specify the criteria for repeating
TACE and the correct number of repeated procedures to under-
take, hence the paper by Adhoute et al. is certainly of interest.
However, it should be noted that patients in more advanced
BCLC stage and with higher baseline AFP levels, namely those
requiring further treatment repetitions are considered less likely1440 Journal of Hepatology 2015 vol. 62 j 1438–1454
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Fig. 1. Overall survival according to ABCR score in a consecutive series of 189
HCC TACE patients performed on-demand at INT-Milan. No signiﬁcant
difference was noted when patients were stratiﬁed by the proposed cut-off score
points (p = 0.19).
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Journal of Hepatology 2015external validation [1–3], although it is known that external val-
idation shows sufﬁcient power to detect clinically important
changes in performance only when substantial sample sizes are
available [5]. With smaller series, as in this study from two
French groups, the sole external validation may have led to an
overestimation of the performance of the model.
A possible often neglected alternative is the internal val-
idation performed by means of bootstrap sampling, aimed at
obtaining a large number of samples randomly drawn with
replacement from the original population [6]. This way, the
model developed in the bootstrap sample is validated in the
original sample and the procedure is repeated, usually at least
100 times [6]. Recent simulation studies recommend, in the
absence of substantially sized external cohorts, internal val-
idation with bootstrapping, because this statistical procedure is
able to simultaneously validate both the model building process
and its performance in a broad range of random samples [5].
We think that prognostication of TACE and indication to
retreatment should rely mostly on well-known clinical and
tumor factors that have to be weighed properly with sounded
estimation methods. On this ground, reﬁnements of the current
point scores computation seems advisable.Financial support
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precision in small samples. J Clin Epidemiol 2003;56:441–447.to beneﬁt from repeated TACE courses by the ﬁnal score. This dis-
crepancy could be explained by the fact that the accuracy of ABCR
score is mostly hampered by the impact of baseline tumoral
parameters (BCLC stage and AFP) on survival. Moreover, many
of the features determining the score are not commonly observed
in conventional intermediate patients undergoing TACE.
In our cohort of 189 consecutive HCC patients treated with
repeated TACEs on demand, only 4/189 (2.1%) patients were in
BCLC C and only 30 (15.8%) presented with an AFP level
P200 IU/ml. In addition, less than 2% of patients were retreated
within 6–8 weeks from original TACE in presence of Child-Pugh
deterioration P2 points. On these premises, and in the absence
of consideration of patient’s performance status, variations in
the ABCR will be largely inﬂuenced by only two covariates: the
early treatment response and the BCLC A/B status, with conse-
quent loss in discriminatory abilities.
In a way, the reduced weight assigned to very common clini-
cal conditions observed in TACE could make the proposed score
scarcely applicable in different contexts, particularly when cur-
rent guidelines for TACE indication are more rigorously followed.
At least, this was the case when the ABCR score was applied to
our series (Fig. 1).
In recent years a number of scores and nomograms have been
proposed to properly guide the therapeutic decision of TACE rep-
etition in HCC patients but none of them unequivocally conﬁrmed
in clinical practice. For instance the Assessment for Repetition of
TACE (ART) score seemed to properly address the need of a reli-
able objective tool easily applicable at bedside [2] but, despite
the initial enthusiasm and the correct methodological approach,
it has not been validated and to the best of our knowledge, has
yet to enter clinical practice. The same can be said of other
numeric scores proposed by other reputed groups [3,4].
All these efforts, although properly conducted, suffer from
overﬁtting: a phenomenon occurring when a model maximizes
its performance on some set of data but its predictive perfor-
mance is not conﬁrmed elsewhere due to random ﬂuctuations
of patients’ characteristics in different clinical and demographical
backgrounds. The very fact that so many different scores keep on
being proposed conﬁrms the excessive importance given to
external validation in preventing overﬁtting.
As in the case of the study by Adhoute et al., the score is tested
in a different but ‘‘plausibly related’’ cohort and that is calledvol. 62 j 1438–1454 1441
[6] Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox
regression model. Stat Med 1989;8:771–783.
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Reply to: ‘‘Repeated transarterial chemoembolization:
An overﬁtting effort?’’
Retreatment with TACE: ABCR score and radiological response, a really tight connection
To the Editor,
We would like to thank Facciorusso et al. for their commentaries
on our article and for applying our ABCR score to their important
cohort of patients.
Transarterial chemoembolization (TACE) is recommended for
intermediate stage hepatocellular carcinoma (HCC) based on
the algorithm of the Barcelona–Clinic Liver Cancer (BCLC) system
[1,2], and is the most widely used treatment for HCC [3].
No consensus exists for treatment methods, number of
courses to be administered, objectives (complete or partial
response, disease stabilization), and retreatment schedule but
performing TACE guided by the radiologic response and individ-
ual tolerance appears to be the most logical option. Moreover, as
suggested by Bolondi et al., intermediate stage represents a
heterogeneous group of patients [4] and, in our group, as in some
other groups, a segmental portal vein thrombosis, corresponding
to BCLC C patients was not considered as an absolute contra-
indication for TACE. This can certainly impact on the efﬁcacy
and tolerance, and is therefore of crucial importance to know
relatively early, at least before severe toxicities, which patients
will beneﬁt from additional sessions.
Table 1. Evolution of median overall survival following ABCR score with different thresholds in a merged cohort of 186 patients treated by TACE.
ABCR ABCR
[-3]
(n = 20)
ABCR
[-2]
(n = 3)
ABCR
[-1]
(n = 52)
ABCR
[0]
(n = 31)
ABCR
[1]
(n = 5)
ABCR
[2]
(n = 34)
ABCR
[3]
(n = 24)
ABCR
[4]
(n = 13)
ABCR 
[5]
(n = 1)
ABCR
[6]
(n = 3)
Median survival 
months [95% CI]
38
[31-72]
31
[26-36]
38
[24-50]
25
[20-27]
24
[3-24]
18
[15-20]
13
[12-15]
7
[6-9]
8
[n.a.]
5
[4-11]
p value <0.0001
Median survival 
months [95% CI]
31 [25-38] 15 [14-19] 7 [6-9]
p value <0.0001
Median survival 
months [95% CI]
37 [31-46] 17 [14-19]
p value <0.0001
Median survival 
months [95% CI]
31 [25-38] 14 [12-17]
p value <0.0001
Median survival 
months [95% CI]
31 [25-38] 14 [12-17]
p value <0.0001
Median survival 
months [95% CI]
26 [24-31] 11 [8-13]
p value <0.0001
Median survival 
months [95% CI]
25 [21-27] 7 [6-9]
p value <0.0001
Letters to the Editor
1442 Journal of Hepatology 2015 vol. 62 j 1438–1454
